Cardiovascular Disease Doctors in Westerly, RI Accepting Medicare

3 Cardiovascular Disease doctors found. Showing 1 - 3

Dr. Stephen M Kutz, M.D., FACC Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 45 Wells St, Suite 102, Westerly, RI 02891 Phone: 401-596-4499    Fax: 401-596-6360

Dr. Jon F Scheiber, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 45 Wells St, Suite 102, Westerly, RI 02891 Phone: 401-596-4499    Fax: 401-596-6360

Howard L Haronian, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 45 Wells St, Suite 102, Westerly, RI 02891 Phone: 401-596-4499    Fax: 401-596-6360

News Archive

Alcohol and prescriptions drug overdose led to massive ambulance call outs last year

According to the latest figures released by Ambulance Victoria overdoses of alcohol and the abuse of prescription drugs is rampant in Melbourne, with more than 14,000 crisis call-outs made to emergency services to combat the excessive use of drugs last year.

Researcher highlights ten main problems that must be addressed to modernize toxicology

Toxicology as a science has not evolved to keep pace with the chemical revolution, according to Thomas Hartung writing in the International Journal of Risk Assessment and Management, Hartung highlights ten problems that must be addressed if toxicology is to be made fit for purpose in the 21st Century.

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

New research from University of the Sciences' Mayes College of Healthcare Business and Policy suggests that MammaPrint - a gene expression profiling (GEP) test used to identify whether women with early-stage breast cancer would benefit from chemotherapy - is the more cost-effective and clinically-useful test than the most frequently used GEP in practice in the United States today.

Creekridge Capital reports record-breaking volume for first quarter 2011

Creekridge Capital LLC, a nationwide independent healthcare and technology vendor leasing company, announced record-breaking volume for first quarter 2011 that exceeds any previous first quarter volume throughout its history.

Read more Medical News

› Verified 4 days ago